Fosun Pharma announced that the registration application for SBK10 oral solution drug by its controlled subsidiary Jinzhou Aohong Pharmaceutical Industry has been accepted by the National Medical Products Administration. This new drug is a chemical drug introduced by Fosun Pharma from Chengdu Sheibei Kang Biomedical Technology Co., Ltd., used to treat mild to moderate acute ischemic stroke.
复星医药：控股子公司新药申请获受理
Fosun Pharma: Controlled subsidiary's new drug application has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated